Novel preclinical patient-derived lung cancer models reveal inhibition of HER3 and MTOR signaling as therapeutic strategies for NRG1 fusion-positive cancers.
暂无分享，去创建一个
M. Ladanyi | G. Ganji | R. Somwar | N. Rekhtman | E. de Stanchina | M. Mattar | M. Offin | M. Asher | Christopher Kurzatkowski | I. Khodos | L. Delasos | I. Odintsov | R. Daly | A. Lui